Gencor’s Levagen+ demonstrates superior absorption in recent PK study

A new pharmacokinetic study published in the Journal of Nutraceuticals and Food Science has demonstrated that Levagen+, Gencor’s palmitoylethanolamide (PEA) ingredient, increased total absorption of PEA by utilising the novel dispersion technology LipiSperse

The parallel, double-blind, absorption study measured the uptake of PEA during a 4-hour period in 28 healthy male and female participants.

The aim of this trial was to determine whether the use of a novel crystalline dispersion technology, LipiSperse, could be successfully used to improve the absorption of PEA.

The results demonstrated that the Levagen+ formulation significantly increased plasma PEA concentration by 1.75 times compared with that of the placebo.

“We are thrilled with the results of this study. To date, there has been limited data on the bioavailability of PEA in human plasma, and this study complements the existing literature showing PEA’s benefits,” said Mariko Hill, Product Development Executive at Gencor.

“The ability to increase PEA within blood plasma can, therefore, potentiate PEA’s positive benefits.”

Palmitoylethanolamide or PEA is a naturally occurring endogenous fatty acid that benefits human health by exerting a variety of biological functions related to aches and discomforts and inflammation.

Study participants were randomised into two groups. Group one consumed a single 300 mg dose of PEA together with the LipiSperse delivery technology (Levagen+), whereas the other group consumed a single 300 mg dose of unprocessed PEA.

Blood samples were taken at baseline and 30, 45, 60, 70, 90, 120, 180, 240 minutes post-ingestion. The primary outcome measure of the trial was the change in plasma uptake of PEA in 4 hours with the resulting area under the curve (AUC), concentration max (Cmax), and maximum change from baseline (Delta Cmax) calculated.

These results indicate that by using the LipiSperse delivery system, PEA absorption is increased above the standard formulation. The maximum concentration of PEA was observed at 45 minutes post ingestion.

LipiSperse, developed by Pharmako Biotechnologies, is an award-winning cold-water dispersible delivery system to help increase bioavailability and functionality of lipophilic ingredients.

Several studies have already demonstrated the technology’s ability to improve absorption of curcumin (HydroCurc), resveratrol (VeriSperse) and Quercetin. LipiSperse can be formulated in powders, tablets, capsules, dietary supplements, and functional foods and beverages.

Companies